BG104058A - Комбинация от тиазолидиндион и сулфонилуреа, състав и използване - Google Patents

Комбинация от тиазолидиндион и сулфонилуреа, състав и използване

Info

Publication number
BG104058A
BG104058A BG104058A BG10405800A BG104058A BG 104058 A BG104058 A BG 104058A BG 104058 A BG104058 A BG 104058A BG 10405800 A BG10405800 A BG 10405800A BG 104058 A BG104058 A BG 104058A
Authority
BG
Bulgaria
Prior art keywords
thiazolydindion
sulphonylurea
diabetes treatment
treatment
insulsin
Prior art date
Application number
BG104058A
Other languages
English (en)
Other versions
BG64817B1 (bg
Inventor
Stephen Smith
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG104058(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712854.0A external-priority patent/GB9712854D0/en
Priority claimed from GBGB9806710.1A external-priority patent/GB9806710D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG104058A publication Critical patent/BG104058A/bg
Publication of BG64817B1 publication Critical patent/BG64817B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Комбинацията се прилага за лечение на захарен диабет (diabetes mellitus), по-специално диабет тип 2, и състояния, свързани със захарен диабет. Комбинацията включва от 2 до 8 mg от 5-[ 4-[2-( N-метил-N-(2-пиридил) амино) етокси] бензил] тиазолидин-2,4-дион (съединение I) или негова тавтомерна форма,или фармацевтично приемливо негово производно в качеството си на инсулинов сенсибилизатор, и сулфонилуреа.
BG104058A 1997-06-18 2000-01-06 Комбинация от тиазолидиндион и сулфонилуреа, състав и използване BG64817B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712854.0A GB9712854D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806710.1A GB9806710D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (2)

Publication Number Publication Date
BG104058A true BG104058A (bg) 2000-10-31
BG64817B1 BG64817B1 (bg) 2006-05-31

Family

ID=26311744

Family Applications (2)

Application Number Title Priority Date Filing Date
BG104058A BG64817B1 (bg) 1997-06-18 2000-01-06 Комбинация от тиазолидиндион и сулфонилуреа, състав и използване
BG109397A BG109397A (bg) 1997-06-18 2000-01-06 Лечение на диабет с тиазолидиндион и сулфонилуреа

Family Applications After (1)

Application Number Title Priority Date Filing Date
BG109397A BG109397A (bg) 1997-06-18 2000-01-06 Лечение на диабет с тиазолидиндион и сулфонилуреа

Country Status (34)

Country Link
EP (3) EP0999845B1 (bg)
JP (1) JP2001523270A (bg)
KR (3) KR20070011651A (bg)
CN (1) CN1168451C (bg)
AP (1) AP1600A (bg)
AR (2) AR012996A1 (bg)
AT (1) ATE353654T1 (bg)
AU (1) AU8539298A (bg)
BG (2) BG64817B1 (bg)
BR (1) BR9810142A (bg)
CA (1) CA2294385C (bg)
CO (1) CO4940457A1 (bg)
CZ (1) CZ299310B6 (bg)
DE (1) DE69837089T2 (bg)
DZ (1) DZ2522A1 (bg)
EA (1) EA003025B1 (bg)
ES (1) ES2283064T3 (bg)
HK (1) HK1028200A1 (bg)
ID (1) ID24065A (bg)
IL (1) IL133137A (bg)
IN (1) IN189319B (bg)
MA (1) MA24571A1 (bg)
MY (1) MY125855A (bg)
NO (3) NO326263B1 (bg)
NZ (1) NZ501163A (bg)
OA (1) OA11510A (bg)
PE (1) PE108199A1 (bg)
PL (2) PL198018B1 (bg)
SK (1) SK286028B6 (bg)
TR (1) TR199903096T2 (bg)
TW (1) TW542717B (bg)
UA (1) UA67743C2 (bg)
UY (1) UY25048A1 (bg)
WO (1) WO1998057649A1 (bg)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
US7166584B1 (en) 1999-11-01 2007-01-23 Wisconsin Alumni Research Foundation Cholesterol transport gene
WO2002055009A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
KR100698595B1 (ko) * 2003-09-29 2007-03-21 보령제약 주식회사 무정형 또는 준결정형 글리메피리드, 이의 제조방법 및 무정형 또는 준결정형 글리메피리드를 포함하는 약학적조성물
NZ546337A (en) * 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
ES2576258T3 (es) 2005-12-22 2016-07-06 Takeda Pharmaceutical Company Limited Preparación sólida que contiene un sensibilizador de insulina
CN104158867B (zh) * 2014-08-06 2017-05-17 电子科技大学 一种基于wave协议的信息多跳转发方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008651A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1992000967A1 (fr) 1990-07-03 1992-01-23 Yamanouchi Pharmaceutical Co., Ltd. Compose biheterocyclique
EP0544696B1 (en) 1990-08-23 1995-01-11 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
KR100249988B1 (ko) 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
TW222626B (bg) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
WO1993021166A1 (en) 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
PL174610B1 (pl) 1992-07-03 1998-08-31 Smithkline Beecham Plc Nowe związki heterocykliczne
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
NO996264L (no) 2000-02-17
CZ299310B6 (cs) 2008-06-18
UY25048A1 (es) 2000-09-29
UA67743C2 (uk) 2004-07-15
BG64817B1 (bg) 2006-05-31
DE69837089D1 (de) 2007-03-29
PE108199A1 (es) 2000-01-14
EA003025B1 (ru) 2002-12-26
CN1168451C (zh) 2004-09-29
TR199903096T2 (xx) 2000-08-21
CN1260719A (zh) 2000-07-19
NZ501163A (en) 2002-02-01
DE69837089T2 (de) 2007-06-21
AP1600A (en) 2006-04-28
ID24065A (id) 2000-07-06
NO2009002I1 (no) 2009-03-02
CA2294385C (en) 2007-06-05
CO4940457A1 (es) 2000-07-24
OA11510A (en) 2004-02-03
PL198018B1 (pl) 2008-05-30
EP2266576A1 (en) 2010-12-29
KR20070011651A (ko) 2007-01-24
ATE353654T1 (de) 2007-03-15
AU8539298A (en) 1999-01-04
KR20010013840A (ko) 2001-02-26
SK179199A3 (en) 2000-11-07
EP1671637A3 (en) 2007-12-19
EP0999845A1 (en) 2000-05-17
TW542717B (en) 2003-07-21
PL337510A1 (en) 2000-08-28
IL133137A (en) 2004-02-08
EA200000039A1 (ru) 2000-08-28
IL133137A0 (en) 2001-03-19
MA24571A1 (fr) 1998-12-31
EP1671637A2 (en) 2006-06-21
HK1028200A1 (en) 2001-02-09
BR9810142A (pt) 2000-08-08
CZ9904577A3 (en) 2001-05-16
IN189319B (bg) 2003-02-08
ES2283064T3 (es) 2007-10-16
AR008025A1 (es) 1999-12-09
BG109397A (bg) 2006-05-31
DZ2522A1 (fr) 2003-02-01
JP2001523270A (ja) 2001-11-20
NO20083276L (no) 2000-02-17
WO1998057649A1 (en) 1998-12-23
AP9901717A0 (en) 1999-12-31
CA2294385A1 (en) 1998-12-23
NO996264D0 (no) 1999-12-17
AR012996A1 (es) 2000-11-22
MY125855A (en) 2006-08-30
NO326263B1 (no) 2008-10-27
SK286028B6 (sk) 2008-01-07
EP0999845B1 (en) 2007-02-14
KR20080011356A (ko) 2008-02-01

Similar Documents

Publication Publication Date Title
BG104060A (bg) Комбинация от тиазолидиндион и метформин, състав и използване
AU2373400A (en) Shelf-stable formulation of glucagon-like peptide-1
BG104135A (bg) Комбинация от тиазолидиндион, средство увеличаващо секрецията на инсулин и бигуанид, фармацевтичен състав и използване
AU3215597A (en) Method of inhibiting fibrosis with a somatostatin agonist
HU9400350D0 (en) Retard peptides
BG105568A (bg) Фармацевтичен състав за модифицирано освобождаване на повишаващо чувствителността към инсулин средство и на друго противодиабетично средство
CA2312839A1 (en) Compositions for nasal administration
MXPA02012763A (es) Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus.
IL126971A0 (en) Interferon compositions
BG104059A (bg) Лечение на диабет с росиглитазон и инсулин
BG104058A (bg) Комбинация от тиазолидиндион и сулфонилуреа, състав и използване
BG104062A (bg) Лечение на диабет с тиазолидиндион, инсулинов секретагог и инхибитор на алфа-глюкозидазата
BG104139A (bg) Лечение на диабет с тиазолидиндион и сулфонилурея
AU6299596A (en) Prevention of a disease having the characteristics of diabetes
GR3018651T3 (en) Treatment of ocular hypertention with a synergistic combination
BR9810186A (pt) Tratamento de diabete com tiazolidinadiona e inibidor de alfa-glicosidade
EP1123100A4 (en) MEMORY IMPROVEMENT BY ADMINISTRATION OF DELTA-5-ANDROSTEN-3-BETA-OL-7,17-DION AND 3-BETA-ESTERS THEREOF
CA2235951A1 (en) Novel uses of mammalian ctla-8 and related reagents
YU28700A (sh) Upotreba potencijatora osetljivosti na insulin u proizvodnji leka za lečenje hiperglikemije
IL143088A0 (en) A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method
MX9709958A (es) Un metodo para reducir la cantidad de insulina exogena administrada a un paciente que tenga diabetes melitus dependiente de insulina.
AU4918900A (en) Interferon-beta use in the treatment of ewing&#39;s family of tumors
MX9701532A (es) Procedimiento para aumentar los niveles de testosterona.
AP2000001787A0 (en) Use of thiazolidinediones for the treatment of hyperglycaemia.
HUP0002669A2 (hu) Diabetes kezelése dioxo-tiazolidinnel és szulfonil-karbamiddal